Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SFT-007
- Development stage
- Preclinical
- Lead developer
- invoX Pharma
- Modality
- Inhalation Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules
- Administration
- Inhalation
01
Overview
SFT-007 is an inhaled therapeutic candidate under development by invoX Pharma for the treatment of Chronic Obstructive Pulmonary Disease (COPD). It utilizes the proprietary Softhaler® technology, a dry powder inhaler (DPI) platform designed to deliver medication effectively to the respiratory tract. As of the current pipeline status, SFT-007 is in the early development or preclinical stage. While the specific active ingredient has not been disclosed, the program aims to leverage the Softhaler® platform's capabilities to improve drug deposition and patient adherence in COPD management.
- Other names
- SFT-007-IVOXSFT007-IVOXSFT 007-IVOX
Beyond the preview
Go deeper on SFT-007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SFT-007.